Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in severe eosinophilic asthma (PRISM)
NCT04276233Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of mepolizumab in eosinophilic asthma (EA), sponsored by GSK. Started Jun 2021; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04276233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276233.